Instead, post-COVID-19 syndrome (PCS) serum and PCS with chronic fatigue syndrome (CFS) serum led to a significant reduction in surface expression of VCAM-1 and E-selectin compared with healthy control serum samples [59]. This evidence concerns the gene VCAM1 and myalgic encephalomeyelitis/chronic fatigue syndrome.